Clinical Trial Update: Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

FT536 is being evaluated in a Phase 1 trial for recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• FT536

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Gynecologic Cancer, Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING